Susquehanna International Group, LLP Arcturus Therapeutics Holdings Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$18.08 - $25.38 $153,680 - $215,730	8,500 Added 13.02%	73,800 $1.71 Million
Q2 2024 Aug 15, 2024	SELL	$24.35 - $44.39 $2.32 Million - $4.22 Million	-95,100 Reduced 59.29%	65,300 $1.59 Million
Q1 2024 May 07, 2024	BUY	$31.23 - $42.99 $584,001 - $803,913	18,700 Added 13.2%	160,400 $5.42 Million
Q4 2023 Feb 14, 2024	BUY	$17.71 - $32.97 $380,765 - $708,855	21,500 Added 17.89%	141,700 $4.47 Million
Q3 2023 Nov 14, 2023	SELL	$25.44 - $37.35 $2 Million - $2.94 Million	-78,800 Reduced 39.6%	120,200 $3.07 Million
Q2 2023 Aug 11, 2023	BUY	$23.94 - $32.36 $1.78 Million - $2.4 Million	74,300 Added 59.58%	199,000 $5.71 Million
Q1 2023 May 16, 2023	BUY	$14.72 - $23.97 $647,680 - $1.05 Million	44,000 Added 54.52%	124,700 $2.99 Million
Q4 2022 Feb 14, 2023	SELL	$14.14 - $23.06 $533,078 - $869,362	-37,700 Reduced 31.84%	80,700 $1.37 Million
Q3 2022 Nov 14, 2022	SELL	$13.05 - $22.13 $388,890 - $659,474	-29,800 Reduced 20.11%	118,400 $1.76 Million

179

25.6M

195K

133K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $451M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.